课题基金 / 基金详情

HEMOGLOBIN INDUCED VASOACTIVITY AND RENAL INJURY

HEMOGLOBIN INDUCED VASOACTIVITY AND RENAL INJURY
血红蛋白引起的血管活性和肾损伤
批准号:
2230768
负责人:
WILFRED LIEBERTHAL
金额:
$33.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-08-01 至 1998-07-31

项目摘要

项目成果

WILFRED LIEBERTHAL的其他基金

相似基金

相关文献

中文摘要
翻译
我们的应用关注的是纯化和蛋白质 无基质血红蛋白(SFH)的修饰不能预防毒性 在动物或人类身上。我们将检验SFH将导致 术后持续的全身和肾内血管收缩 氧合血红蛋白被新陈代谢。我们还将检验这一假设 SFH的未改性和改性制剂都有可能 在两个不同的环境中导致急性肾功能衰竭(ARF): A.我们假设SFH在以下情况下会加重肾脏损伤 在已确定的肾功能衰竭引起的原因后不久给予 肾缺血的一段时间。 B.我们假设SFH将导致“从头”ARF(在不存在的情况下 已确诊的肾损伤),当大剂量给药时,“有疗效” 失血性休克后的剂量。 我们的具体目标是: 1.检测和比较大鼠血管收缩的机制。 未改性和改性SFH。 我们将研究氧合血红蛋白抑制一氧化氮的机制。 氧化物介导的血管松弛确定蛋白质修饰是否 可能会减少这种与血管收缩相关的原因 未经修改的SFH 我们将研究内皮素释放在SFH相关疾病中的作用 血管收缩。 2.验证SFH诱导中性粒细胞介导的假说 血管内皮损伤。 我们将研究未经修改和修改的SFH形式的影响,以及 其代谢产物氯化血红素对中性粒细胞-内皮细胞黏附的影响 中性粒细胞诱导的内皮损伤。致病机制 参与SFH诱导的中性粒细胞-黏附相互作用 已澄清。 3.检查和比较未修改和修改的程度 SFH加重潜在的已建立的缺血性肾损伤。 4.检查未修改和修改的SFH导致De的程度 大剂量SFH致低血容量后的Novo ARF 动物。 我们将检验我们的假设,即肾功能衰竭将在几天内诱发。 在给低血压大鼠注射SFH后, A)延长肾内血管收缩的综合效应b) 有毒代谢物(氯化血红素和游离铁)在肾脏中的积累 实质和c)中性粒细胞诱导的内皮损伤。
英文摘要
Our application is focused on the concern that purification and protein modification of stroma free hemoglobin (SFH) will not prevent toxicity in animals or humans. We will examine the hypothesis that SFH will cause prolonged systemic and intrarenal vasoconstriction persisting after the oxyhemoglobin is metabolized. We also will examine the hypothesis that both unmodified and modified preparations of SFH have the potential to cause acute renal failure (ARF) in two distinct settings: a. We hypothesize that SFH will exacerbate renal injury when administered shortly after established renal failure has been caused by a period of renal ischemia. b. We hypothesize that the SFH will cause "de novo" ARF (in the absence of established renal injury) when administered in large, "therapeutic" doses following hemorrhagic shock. Our specific aims are: 1. To examine and compare the mechanisms of vasoconstriction induced by unmodified and modified SFH. We will examine the mechanism by which oxyhemoglobin inhibits nitric oxide mediated vasorelaxation to determine whether protein modification is likely to reduce this cause of vasoconstriction associated with unmodified SFH We will examine the role of endothelin release in SFH-associated vasoconstriction. 2. To test the hypothesis that SFH will induce neutrophil mediated endothelial injury. We will examine the effects of unmodified and modified forms of SFH and its metabolite hemin on neutrophil-endothelial cell adhesion and neutrophil-induced endothelial injury. The pathogenetic mechanisms involved in the SFH induced neutrophil-adhesion interactions will be elucidated. 3. To examine and compare the extent to which unmodified and modified SFH exacerbates underlying established ischemic renal injury. 4. To examine the extent to which unmodified and modified SFH cause de novo ARF after the administration of large amounts of SFH to hypovolemic animals. We will examine our hypothesis that renal failure will be induced days after the administration of SFH to hypotensive rats resulting from the combined effects of a) prolonged intrarenal vasoconstriction b) the accumulation of toxic metabolites (hemin and free iron) in the renal parenchyma and c) neutrophil-induced endothelial injury.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MECHANISMS OF RENAL TUBULAR EPITHELIAL CELL INJURY
  • 批准号:
    6381402
  • 项目类别:
  • 资助金额:
    $38.18万
  • 财政年份:
    1998
  • 负责人:
    WILFRED LIEBERTHAL
  • 依托单位:
MECHANISMS OF RENAL TUBULAR EPITHELIAL CELL INJURY
  • 批准号:
    2620495
  • 项目类别:
  • 资助金额:
    $35.32万
  • 财政年份:
    1998
  • 负责人:
    WILFRED LIEBERTHAL
  • 依托单位:
MECHANISMS OF RENAL TUBULAR EPITHELIAL CELL INJURY
  • 批准号:
    6177728
  • 项目类别:
  • 资助金额:
    $37.31万
  • 财政年份:
    1998
  • 负责人:
    WILFRED LIEBERTHAL
  • 依托单位:
MECHANISMS OF RENAL TUBULAR EPITHELIAL CELL INJURY
  • 批准号:
    2906066
  • 项目类别:
  • 资助金额:
    $36.38万
  • 财政年份:
    1998
  • 负责人:
    WILFRED LIEBERTHAL
  • 依托单位:
国内基金
海外基金
内皮素Endothelin-1诱导皮层扩散性抑制的在体光学成像研究
  • 批准号:
    30500115
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    29.0万元
  • 批准年份:
    2005
  • 负责人:
    李鹏程
  • 依托单位: